Hls Therapeutics, Inc. · TSX:HLS
Hls Therapeutics — Q1 2022 Earnings Presentation
6 slides from Hls Therapeutics's earnings presentation, May 5, 2022
Slide 1: Q1 2022 Results Conference Call
Gilbert Godin | CEO Tim Hendrickson | CFO Q1 2022 Results Conference Call May 5, 2022 TSX - HLS
Slide 2: Forward-looking statements
Forward-looking statements Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not alwa
Slide 3: Vascepa: strong rebound in physician interaction in March
Vascepa: strong rebound in physician interaction in March 40% decrease in average number of live calls in January/February 13% of January/February calls were in-person March call activity reaches new monthly high >80% of March calls were in-person Sept Oct Nov Dec Jan Feb March Live Call Volume Prov
Slide 4: Impact of Omicron on large CV markets in Q1 2022
Impact of Omicron on large CV markets in Q1 2022 Demand Growth: Q1 '22 vs Q4 '21 (TRx units) 15% 12% 10% Vascepa grew Rx 5% volumes 12% in Q1 despite Omicron 0% -2% headwinds -5% -4% -5% -5% -8% -10% Statins Bile Acid Seq Fibrates Ezetimibe PCSK9 Vascepa VASCEPA Provided May 5, 2022, as part of an o
Slide 5: Vascepa: prescription momentum growing
Vascepa: prescription momentum growing… 900 Weekly script data since launch …fueled by growth catalysts 800 700 Private market access • >90% eligible for coverage 600 Inclusion in Canadian medical Prescriptions 500 society guidelines • Canadian Cardiovascular Society, Heart & Stroke, Thrombosis Cana
Slide 6: Q1 2022 Results Conference Call
Gilbert Godin | CEO Tim Hendrickson | CFO Q1 2022 Results Conference Call May 5, 2022 TSX - HLS